Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PP-002
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-002
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Qingdao Primedicine Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 19, 2020
Details:
Under the terms of the Partnership, Primedicine receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets. Financial terms were not disclosed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PP-001
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PP-001
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Simcere Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 11, 2020
Details:
Simcere receives exclusive rights to develop and commercialize in China, including the mainland, Hong Kong, Macau and Taiwan while Primary Peptides retains rights in all other markets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): K13
Therapeutic Area: Cardiology/Vascular Diseases Product Name: K13
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Yabao Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 15, 2015
Details:
Yabao receives exclusive rights to develop and commercialize innovative products targeting PTEN nuclear translocation for the treatment of stroke in China, Taiwan and Hong Kong while Primary Peptides retains rights in all other markets.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
